I like that thought. I went back and re-read the Streetwise piece again with that thought in mind and looking at what Leo was telling us, that could very well be a strong possibility. The other possibility I thought of is Leo is still confident as ever in getting deals or partnerships at his price and not someone else's. So he is still comfortable, willing, and able to use existing funding sources to keep the trials going at current market conditions. I like that less in the short term because I think it means the SP continues to languish a little bit, but in the long term that continues to tell me that CTIX has the goods and they know it. No need to take an unfavorable deal if they can bear a little more short term pain, finish some more trials, and then get a great deal later.
As I see it CTIX is going to have funds to finish all current trials (K Ph1, B-OM Ph2, P Ph2) and is currently able to fund K Ph2 for ovarian cancer, B Ph3 for ABSSSI, and B Ph1 or 2 for ulcerative proctitis. If the grant application for Pancreatic Cancer comes through then that one will be added to list too.
That is quite a fantastic resume of progress in 2016 that CTIX can currently afford. So what excites me are the known & unknown items Leo has waiting in the queue to start if the market valuation returns to a more realistic number, or if someone makes him that excellent partnership/licensing offer which he is holding for.
Leo's quotes:
"LE: At this time, we feel that with our cash on hand, the commitment from Aspire and our shelf registration, we have sufficient funding options to complete the Phase 3 ABSSSI trial, as well as continue our other clinical studies and move forward with additional laboratory work. Of course, everything is subject to market conditions."
"LE: Yes, it is at the top of our list of goals for 2016. In addition to the ovarian cancer study with Kevetrin and the ABSSSI Phase 3 with brilacidin, we also plan on starting a brilacidin trial for ulcerative proctitis in March."